Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

National Survey on Asthma (SYMPTOMES)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: October 7, 2008
Last updated: November 30, 2010
Last verified: November 2010

To evaluate the concordance of the most frequently used words by the patients and the physicians to express asthma symptoms, according to the patient's level of asthma control.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: A Mirror Assessment of the Words Used By Patients and Physicians to Express Asthma Symptoms, According To the Patient's Level of Asthma Control In General Medicine

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The concordance of the most frequently used words by the patients and the physicians to express asthma symptoms, according to the patient's level of asthma control. [ Time Frame: Once ] [ Designated as safety issue: No ]

Enrollment: 1704
Study Start Date: September 2008
Study Completion Date: March 2009

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The first 2 consecutive patients seen during the GP's visit with a diagnosis of persistent asthma


Inclusion Criteria:

  • A diagnosis of persistent asthma treated with an inhaled corticosteroid based maintenance treatment for more than 3 months
  • Given his/her consent to participate to the study and who is able to answer the questionnaire in french by him/her-self.

Exclusion Criteria:

  • Patient with a cardiac disease (congestive heart failure, coronary artery disease)
  • Patient with a respiratory disease other than asthma (COPD, sleep apnea syndrome).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00770250

  Show 910 Study Locations
Sponsors and Collaborators
Study Director: Alain Castaigne AstraZeneca
  More Information

No publications provided

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals Identifier: NCT00770250     History of Changes
Other Study ID Numbers: NIS-RFR-DUM-2008/1
Study First Received: October 7, 2008
Last Updated: November 30, 2010
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
asthma symptoms
words used by patients and physicians
express asthma symptoms

Additional relevant MeSH terms:
Bronchial Diseases
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases processed this record on March 01, 2015